Fidelity Global Health Care Series B (FID299)
68.25
-0.45
(-0.65%)
CAD |
Jan 12 2026
Returns Chart
Key Stats
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 2.25% | 179.43M | 0.98% | 19.63% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -30.74M | 0.40% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The Fund aims to achieve long-term capital growth. It invests primarily in equity securities of companies anywhere in the world that design, make or sell products or services related to health care and medicine. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Large Cap Core |
| Broad Asset Class | Miscellaneous |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health Care Equity |
| Global Macro | Equity Industry Sector |
| US Macro | -- |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | -- |
| Fund Owner Firm Name | Fidelity Investments |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
85
-38.14M
Peer Group Low
74.26M
Peer Group High
1 Year
% Rank:
80
-30.74M
-338.43M
Peer Group Low
246.96M
Peer Group High
3 Months
% Rank:
60
-186.09M
Peer Group Low
59.76M
Peer Group High
3 Years
% Rank:
69
-812.56M
Peer Group Low
555.36M
Peer Group High
6 Months
% Rank:
67
-181.73M
Peer Group Low
92.55M
Peer Group High
5 Years
% Rank:
58
-531.99M
Peer Group Low
1.261B
Peer Group High
YTD
% Rank:
--
-975839.0
Peer Group Low
-975839.0
Peer Group High
10 Years
% Rank:
54
-322.46M
Peer Group Low
1.506B
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of January 14, 2026.
Asset Allocation
As of November 30, 2025.
| Type | % Net |
|---|---|
| Cash | 0.37% |
| Stock | 99.33% |
| Bond | 0.04% |
| Convertible | 0.00% |
| Preferred | 0.00% |
| Other | 0.26% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Boston Scientific Corp. | 8.09% | 94.10 | -1.69% |
| AstraZeneca PLC | 6.44% | 188.66 | 1.71% |
| Roche Holding AG | 6.28% | 426.00 | -0.19% |
| Stryker Corp. | 5.74% | 355.78 | -1.55% |
| AbbVie, Inc. | 5.32% | 220.75 | 0.32% |
| Danaher Corp. | 4.76% | 235.66 | -1.40% |
| Abbott Laboratories | 4.67% | 124.25 | -0.31% |
| UCB SA | 4.42% | 304.84 | 1.50% |
| UnitedHealth Group, Inc. | 3.91% | 333.93 | -1.93% |
| Alnylam Pharmaceuticals, Inc. | 3.59% | 369.77 | -0.31% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | -- |
| Actual Management Fee | -- |
| Administration Fee | -- |
| Maximum Front Load | -- |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | -- |
| General Availability | |
| Available for Insurance Product | No |
| Available for RRSP |
|
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 500.00 None |
| Minimum Subsequent Investment | 25.00 None |
Basic Info
| Investment Strategy | |
| The Fund aims to achieve long-term capital growth. It invests primarily in equity securities of companies anywhere in the world that design, make or sell products or services related to health care and medicine. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Large Cap Core |
| Broad Asset Class | Miscellaneous |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health Care Equity |
| Global Macro | Equity Industry Sector |
| US Macro | -- |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | -- |
| Fund Owner Firm Name | Fidelity Investments |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (1-12-26) | 0.00% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | 46 |
| Stock | |
| Weighted Average PE Ratio | 37.84 |
| Weighted Average Price to Sales Ratio | 7.050 |
| Weighted Average Price to Book Ratio | 8.810 |
| Weighted Median ROE | 322.8% |
| Weighted Median ROA | 9.16% |
| ROI (TTM) | 13.24% |
| Return on Investment (TTM) | 13.24% |
| Earning Yield | 0.0319 |
| LT Debt / Shareholders Equity | 3.711 |
| Number of Equity Holdings | 38 |
As of November 30, 2025
Growth Metrics
| EPS Growth (1Y) | 16.49% |
| EPS Growth (3Y) | 9.60% |
| EPS Growth (5Y) | 12.24% |
| Sales Growth (1Y) | 11.02% |
| Sales Growth (3Y) | 7.61% |
| Sales Growth (5Y) | 10.47% |
| Sales per Share Growth (1Y) | 11.37% |
| Sales per Share Growth (3Y) | 8.15% |
| Operating Cash Flow - Growth Rate (3Y) | 6.41% |
As of November 30, 2025
Fund Details
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:FID299.TO", "name") |
| Broad Asset Class: =YCI("M:FID299.TO", "broad_asset_class") |
| Broad Category: =YCI("M:FID299.TO", "broad_category_group") |
| Prospectus Objective: =YCI("M:FID299.TO", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |